Dr. Pat Whitworth on the Importance of the Luminal Subtype in Breast Cancer
Whitworth says that while it is generally perceived that the ER-positive/HER2-negative breast cancer patient population is the luminal subtype, 1 of every 5 of those patients would actually considered basal subtype.
Pat Whitworth, MD, breast surgical oncologist, Nashville Breast Center, discusses how the discovery of luminal subtyping in breast cancer changed the paradigm of treatment. Whitworth says that while it is generally perceived that the ER-positive/HER2-negative breast cancer patient population is the luminal subtype, 1 of every 5 of those patients would actually considered basal subtype. Whitworth says the reason this is important, is that the basal subtype normally has a much higher pathological complete response rate than the luminal subtype.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
